U.K.: Benefits outweigh risks for AstraZeneca despite 7 deaths
LONDON — Britain’s medicines regulator is urging people to continue taking the AstraZeneca coronavirus vaccine, despite revealing that seven people in the U.K. have died from rare blood clots after getting the jab.
The Medicines and Healthcare Regulatory Agency, or MHRA, said it wasn’t clear if the shots are causing the clots, and that its “rigorous review into the U.K. reports of rare and specific types of blood clots is ongoing.”
Though the agency said late Friday that seven people had died as a result of developing blood clots, it didn’t disclose any information about their ages or health conditions.
In total, MHRA said it had identified 30 cases of rare blood clot events out of 18.1 million AstraZeneca doses administered up to and including March 24. The risk associated with this type of blood clot is “very small,” it added.
“The benefits of COVID-19 vaccine AstraZeneca in preventing COVID-19 infection and its complications continue to outweigh any risks and the public should continue to get their vaccine when invited to do so,” said Dr. June Raine, the agency’s chief executive.
Concerns over the AstraZeneca vaccine have already prompted some countries including Canada, France, Germany
and the Netherlands to restrict its use to older people.
The U.K., which has rolled out coronavirus vaccines faster than other European nations, is particularly reliant on the AstraZeneca vaccine, which was developed by scientists at the University of Oxford. It has also been using the vaccine developed by Pfizer-BioNTech, of which the agency has not seen any reported blood clot events.
Figures Saturday showed that the U.K. has given a first dose of vaccine to 31.4 million people, or around 46% of its population, a much higher rate than the rest of Europe. Delivering second doses is the priority for April, with 5.2 million people now having received two jabs.